|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 HKD | +3.33% |
|
+4.38% | -7.19% |
| Apr. 15 | Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug | MT |
| Apr. 15 | Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China | CI |
Ocumension Therapeutics reported earnings results for the full year ended December 31, 2021. For the full year, the company reported sales was CNY 56.15 million compared to CNY 13.1 million a year ago. Net loss was CNY 259.99 million compared to CNY 2,264.87 million a year ago.
Basic loss per share from continuing operations was CNY 0.43 compared to CNY 7 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -7.19% | 534M | |
| +24.17% | 562B | |
| -6.33% | 358B | |
| +19.90% | 322B | |
| +7.95% | 297B | |
| +13.45% | 219B | |
| +6.04% | 199B | |
| -10.51% | 196B | |
| -12.26% | 149B | |
| -6.47% | 146B |
OCUMENSION THERAPEUTICS 
